{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T13:40:33Z","timestamp":1736602833271,"version":"3.32.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.endien.2024.12.004","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T12:25:07Z","timestamp":1735302307000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Status of type 1 diabetes mellitus prevention: promises and realities"],"prefix":"10.1016","volume":"72","author":[{"given":"Ana M.","family":"W\u00e4gner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Hern\u00e1ndez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2024.12.004_bib0005","unstructured":"Guideline on clinical investigation of medicinal products in the prevention and treatment of diabetes (CPMP\/EWP\/1080\/00 Rev.2) European Medicines Agency 2023 (https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-revision-2_en.pdf, consultada 08.10.24)."},{"key":"10.1016\/j.endien.2024.12.004_bib0010","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.endien.2024.12.004_bib0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s43856-023-00357-y","article-title":"Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review","volume":"3","author":"Felton","year":"2023","journal-title":"Commun Med (Lond)."},{"key":"10.1016\/j.endien.2024.12.004_bib0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.12.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177492","article-title":"Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes","volume":"134","author":"Lled\u00f3-Delgado","year":"2024","journal-title":"J Clin Invest."},{"key":"10.1016\/j.endien.2024.12.004_bib0030","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4239\/wjd.v15.i8.1793","article-title":"Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: a systematic review","volume":"15","author":"Buddhavarapu","year":"2024","journal-title":"World J Diabetes."},{"key":"10.1016\/j.endien.2024.12.004_bib0035","unstructured":"Food and drug administration. https:\/\/www.fda.gov\/media\/164864\/download, accessed 08.10.24."},{"key":"10.1016\/j.endien.2024.12.004_bib0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/d41591-022-00115-y","article-title":"FDA approves first drug to delay type 1 diabetes","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat Med."},{"key":"10.1016\/j.endien.2024.12.004_bib0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S2213-8587(22)00390-4","article-title":"Teplizumab approval for type 1 diabetes in the USA","volume":"11","author":"Evans-Molina","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.12.004_bib0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S2213-8587(22)00384-9","article-title":"Teplizumab approval for type 1 diabetes in the USA","volume":"11","author":"Beran","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.12.004_bib0055","unstructured":"Food and Drug Administration US. Tzield Full prescribing information. Reference ID: 5079828 FDA [accessed 12 Oct 2024]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761183s000lbl.pdf."},{"key":"10.1016\/j.endien.2024.12.004_bib0060","unstructured":"Sanofi Press Release: Sanofi completes acquisition of Provention Bio, Inc. 2023 [accessed 12 Oct 2024]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-04-27-12-40-19-2656379."},{"key":"10.1016\/j.endien.2024.12.004_bib0065","unstructured":"Sanofi. It\u2019s finally time to get a step ahead. 2024 [accessed 12 Oct 2024]. Available from: https:\/\/www.tzield.com."},{"key":"10.1016\/j.endien.2024.12.004_bib0070","unstructured":"Innodia. We strive for a world without type 1 diabetes. 2023 [accessed 12 Oct 2024]. Available from: www.innodia.org."},{"issue":"Suppl A35","key":"10.1016\/j.endien.2024.12.004_bib0075","article-title":"Screening and monitoring for presymptomatic type 1 diabetes: the DiaUnion project","author":"Hviid Kl\u00e6bel","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.endien.2024.12.004_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1386513","article-title":"Home capillary sampling and screening for type 1 diabetes, celiac disease, and autoimmune thyroid disease in a Swedish general pediatric population: the TRIAD study","volume":"12","author":"Naredi Scherman","year":"2024","journal-title":"Front Pediatr"},{"key":"10.1016\/j.endien.2024.12.004_bib0085","unstructured":"Gazzetta Ufficiale della Repubblica Italiana. Legge 15 settembre 2023, n 130: Disposizioni concernenti la definizione di un programma diagnostico per l\u2019individuazione del diabete di tipo 1 e della celiachia nella popolazione pediatrica. (23G00140) [accessed 12 Oct 2024]. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2023\/09\/27\/226\/sg\/pdf."},{"key":"10.1016\/j.endien.2024.12.004_bib0090","unstructured":"The ELSA Study [accessed 12 Oct 2024]. Available from: www.elsastudy.org."},{"key":"10.1016\/j.endien.2024.12.004_bib0095","unstructured":"T1DRA. Type 1 Diabetes Risk in Adults [accessed 12 Oct 2024]. Available from: https:\/\/t1dra.bristol.ac.uk."},{"year":"2020","series-title":"Screening programs: a short guide","key":"10.1016\/j.endien.2024.12.004_bib0100"},{"key":"10.1016\/j.endien.2024.12.004_bib0105","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-024-06205-5","article-title":"Consensus guidance for monitoring individuals with islet autoantibody\u2013positive pre-stage 3 type 1 diabetes","volume":"67","author":"Phillip","year":"2024","journal-title":"Diabetologia"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018024001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018024001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T10:04:32Z","timestamp":1736503472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018024001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2530018024001409"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2024.12.004","relation":{},"ISSN":["2530-0180"],"issn-type":[{"type":"print","value":"2530-0180"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status of type 1 diabetes mellitus prevention: promises and realities","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2024.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2024.10.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}